Halcygen reports maiden profit
Wednesday, 01 September, 2010
Antibiotic developer Halcygen Pharmaceuticals has reported a maiden net profit of $3.25 million for the year ended June 30, 2010, largely driven by the company’s acquisition of Mayne Pharma International last year from Hospira Inc.
The result contrasts with a loss of $3.76 million reported for the previous year.
The company reported EBITDA (earnings before interest, tax, depreciation and amortisation) of $12.2 million, noting however that the figure would have been higher were it not for a high Australian dollar throughout the period.
Adjusting US sales of its oral antibiotic Doryx for current foreign exchange rates, sales were up eight percent year on year to ovr $200 million. Halcygen attributed much of its improved performance to the acquisition of drug developer Mayne Pharma International in September last year, a move which the company described as ‘transformational’.
Halcygen declared a dividend of two cents per share, indicating that it also expected to make a special dividend of one cent per share payable in the first half of the next calendar year following a review of the half-year results.
Anti-inflammatory agent could decrease septic shock mortality
Researchers have discovered a naturally occurring blood protein — a type of...
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
